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a  b  s  t  r a  c t
Aprataxin, aprataxin  and  PNKP-like  factor  (APLF)  and  polynucleotide  kinase phosphatase  (PNKP)  are key
DNA-repair proteins  with  diverse functions but  which  all contain  a  homologous  forkhead-associated
(FHA)  domain.  Their  primary binding targets  are casein  kinase  2-phosphorylated  forms  of the  XRCC1  and
XRCC4 scaffold  molecules  which  respectively  coordinate  single-stranded and  double-stranded  DNA break
repair  pathways.  Here,  we present  the  high-resolution  X-ray  structure of a complex of phosphorylated
XRCC4 with  APLF,  the most divergent  of the  three  FHA  domain  family  members.  This,  combined with
NMR and  biochemical  analysis  of aprataxin  and APLF  binding to singly  and  multiply-phosphorylated
forms of XRCC1 and XRCC4, and comparison  with  PNKP reveals a pattern  of distinct  but  overlapping
binding specificities  that  are  differentially  modulated  by  multi-site  phosphorylation.  Together,  our data
illuminate  important  differences  between  activities  of  the  three phospho-binding  domains,  in spite  of a
close  evolutionary  relationship  between them.
© 2015  The Authors.  Published by  Elsevier  B.V.  This is an open  access article  under  the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Genome integrity is under constant threat from a  variety of
endogenous and exogenous genotoxic agents, which create a
broad spectrum of both single-stranded and double-stranded DNA
lesions. Failure to repair such breaks can result in cell death
or tumor development. Several complex repair pathways have
evolved to resolve various types of DNA lesions; these involve
stages of break detection, DNA end-processing, DNA gap filling
and DNA ligation. XRCC1 is a  crucial scaffolding protein in base
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excision repair that interacts with and coordinates many known
components of that pathway. These include poly(ADP-ribose) poly-
merase 1 (PARP-1) [1,2], polynucleotide kinase phosphatase (PNKP)
[3],  aprataxin [4–8],  aprataxin- and PNKP-like factor (APLF) [9,10],
DNA polymerase  [1,11] and DNA ligase III [12,13].  XRCC4 has
a parallel role in the non-homologous end-joining (NHEJ) pathway
for repair of double-stranded DNA breaks where it interacts with
the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs)
[14,15],  PNKP [16],  aprataxin [4], APLF [17,18] and DNA ligase IV
[19,20].
Whilst many of the repair pathway components bind to different
domains on the scaffolding proteins, three DNA-end modifica-
tion proteins PNKP, aprataxin and APLF potentially compete for
the same binding sites on XRCC1 and XRCC4. PNKP has dual
activities; it phosphorylates 5′-OH termini and dephosphorylates
3′-phosphate termini which occur in  >50% of breaks induced
by oxidative stress [21,22].  Aprataxin removes AMP  from 5′-
adenylated DNA which can be  formed when DNA ligation is  aborted
prematurely [23].  The precise role of APLF is  yet to be deter-
mined although it does possess both endo- and exo-nuclease
activity and its depletion is associated with impairment of NHEJ
[18].  These three proteins share highly homologous forkhead-
associated (FHA) domains (Fig.  1A), which have been shown to
http://dx.doi.org/10.1016/j.dnarep.2015.10.002
1568-7864/© 2015 The Authors. Published by Elsevier B.V. This is  an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Domain structure and CK2-phosphorylation sites of DNA repair proteins.
(A)  Schematic representation showing forkhead-associated (FHA), histidine triad
(HIT), Ku-binding (KB), zinc  finger (ZF), kinase and phosphatase domains of
aprataxin, APLF and PNKP. (B) Schematic representation of N-terminal (NTD),
BRCA1C-terminal (BRCT) and coiled-coil (CC) domains of XRCC1 and XRCC4 and
interspecies sequence conservation of CK2 sites. Positions of CK2-phosphorylation
sites in the core motif are denoted with yellow spheres and subsidiary CK2-sites
denoted with green spheres. Core motif residues conserved in  both XRCC1 and
XRCC4 are highlighted in red and residues conserved within XRCC1 or XRCC4 are
highlighted in light blue.
function as protein–protein interaction modules through their
specific recognition of phosphothreonine-containing motifs on
interacting partners [24–30].  All three bind XRCC1 and XRCC4
in a casein kinase 2 (CK2)-dependent manner [4,9,10,16–18,31].
Comparison of CK2 sites in  XRCC1 and XRCC4 reveals a common
YxxSTDE core motif, in  which both serine and threonine are phos-
phorylated, with subsidiary sites present C-terminal to the core
motif (Fig. 1B). Both PNKP and aprataxin FHA domains can bind a
triphosphorylated peptide derived from this region of XRCC1 [7,32]
and for PNKP each phosphate has been shown to contribute to bind-
ing affinity. Here, we systematically investigate the role of each
of the XRCC1 and XRCC4CK2-phosphorylated residues in  binding
of the aprataxin and APLF FHA domains. The crystal structure of
the  APLF FHA domain bound to a triphosphosphorylated XRCC4
peptide, together with NMR titration experiments of aprataxin and
XRCC1 peptides are  used to  explore the structural basis for multi-
ple phospho-peptide binding. Together, these data reveal distinct
but overlapping binding modes and specificities for this important
family of DNA-damage responsive FHA domain proteins that are, in
turn, differentially regulated by multi-site phosphorylation of their
binding targets.
2. Materials and methods
2.1. Protein expression and purification
The genes for aprataxin residues 1–105 and APLF residues
1–106 were amplified using primer sets which incorporated 5′
BamHI and 3′ XhoI sites. PCR products and pGEX-6P-1 vector were
digested with BamHI and XhoI and religated. All point mutations
were generated using a  QuickChange Site-Directed Mutagenesis Kit
(Stratagene) following the manufacturer’s recommended protocol.
For expression, the pGEX-6P-1/aprataxin-FHA constructs were
transformed into Escherichia coli strain BL21 (DE3) and the pGEX-
6P-1/APLF-FHA constructs transformed into the strain Rosetta2
(DE3). Cells were grown in  LB at 37 ◦C to an A600 of 0.5, induced
with 0.4 mM  isopropyl 1-thio--d-galactopyranoside and incu-
bated at 18 ◦C for a  further 16 h before harvesting. Cells were lysed
by sonication and clarified by centrifugation (20,000 ×  g  × 30 min).
The supernatant was applied to a  glutathione-4B resin (Amer-
sham) and cleaved from the resin with rhinovirus 3C protease.
Proteins were purified further by gel-filtration chromatography on
a Superdex 75 matrix in 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM
DTT. Selenomethionine-labelled APLF L91 M protein was expressed
in Rosetta2 (DE3) cells cultured in SelenoMet base media and nutri-
ents supplemented with seleno-methionine solution (Molecular
Dimensions Ltd.) and purified as the wild-type protein.
2.2. Isothermal titration calorimetry
Phosphopeptides based on the XRCC1 sequence
515-YAGSTDENTDSEEHQ-529 and the XRCC4 sequence 229-
YDESTDEES-237 were synthesised with amidated C-termini to
avoid potential end-effects of a  free carboxy-terminus by Dr.  W.
Mawby (University of Bristol), purified by HPLC and characterised
by  mass spectrometry. FHA-phosphopeptide binding was quanti-
fied by isothermal titration calorimetry using a Microcal Omega
VP-ITC calorimeter (MicroCal Inc., Northampton, MA). Protein was
dialysed against ITC buffer (50 mM HEPES pH 7.5, 150 mM  NaCl,
5 mM  -mercaptoethanol) and peptides were dissolved in  the
dialysis buffer. Experiments were carried out at 22 ◦C and involved
30 successive 10 l  injections of peptide solution into a  sample cell
containing protein solution. Titrations with XRCC1 peptides used
peptide at 1 mM and protein at 100 M and titrations with XRCC4
peptides used peptide at 300 m and protein at 30 M. Heats of
dilution were subtracted and binding isotherms were plotted and
analysed with MicroCal origin version 7.0, assuming a single-site
binding model.
2.3. Crystallization and structure determination
Selenomethionine-labelled protein and peptide were combined
in  a  1:3 ratio, with protein at a concentration of 10 mg/ml, in 50 mM
HEPES pH 7.5, 150 mM  NaCl, 5 mM -mercaptoethanol. The com-
plex crystallised from hanging drops set up at 18 ◦C with equal
volumes of protein and reservoir solution 0.1 M Tris pH 8.0, 30%
w/v PEG 3350, 0.2 M MgCl2.  Crystals grew within one week and
were transferred into cryoprotectant (50 mM  Tris pH 8.0, 15% w/v
PEG 3350, 0.1 M MgCl2, 75 mM  NaCl, 25 mM HEPEs pH 7.5) and flash
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Table 1
Crystallographic statistics.
Data collection APLF/XRCC4 SeMet
Space group P  212121
Cell dimensions
a, b, c (Å) 38.50 58.54 94.93
˛, ˇ,  (◦)  90.0, 90.0, 90.0
Wavelength (Å) 0.98050
Resolution (Å) 30.0–1.38 (1.42–1.38)a
Rmerge
b 5.3 (39.9)
I/ I 26.7 (3.7)
Completeness (%) 97.8 (80.4)
Redundancy 6.5 (5.1)
Refinement
Resolution (Å) 28.0–1.38
No.  reflections 43,936
Rwork
c/Rfreed (%) 13.7/17.4
No. atoms
Protein 1736
Ligand/ion 147
Water 402
B-factors
Protein 14.5
Ligand/ion 26.3
Water 33.4
R.m.s deviations
Bond lengths (Å) 0.011
Bond angles (◦) 1.36
a Statistics for outer resolution shell.
b Rmerge =
∑
hkl
∑
i | Ii −  I |/
∑
hkl
∑
Ii where Ii is the intensity of the ith
measurement of a reflection with indexes hkl and I is  the  statistically weighted
average reflection intensity.
c R-work =
∑
||Fo|  − |Fc||/
∑
|Fo|  where Fo  and Fc are the observed and calculated
structure factor amplitudes, respectively.
d Rfree is the R-factor calculated with a  random 5% of the reflections omitted from
refinement.
frozen in liquid nitrogen. X-ray diffraction data were collected at
a single wavelength of 0.9805 Å on beamline I03 of the Diamond
Light Source using an ADSC CCD detector. A  total of 720 images
were collected with an oscillation angle of 1◦ and an exposure time
of 0.5 s per image. Data were integrated and scaled using DENZO
and SCALEPACK [33] and SAD phasing and structure solution car-
ried out by the Autosol wizard of the PHENIX software package [34].
Subsequent refinement was carried out at 1.4 Å using the PHENIX
refine module of the PHENIX software package and manual model
building in Coot [35].  Data collection and refinement statistics are
summarised in Table 1.  All  structure figures were prepared with
PyMol (http://www.pymol.org).
2.4. NMR  spectroscopy
NMR  experiments were carried out at 22 ◦C on Bruker Avance
II+ 600 MHz  and Avance III 700 MHz  spectrometers, each equipped
with a cryogenic triple-resonance probe. Protein and peptides
were prepared in NMR  buffer (20 mM Na Acetate pH 5.8, 50 mM
NaCl, 2 mM  DTT). Three-dimensional HNCA, HNCO, HNCACB and
CBCA(CO)NH experiments were performed to obtain backbone
assignments. NMR  titration experiments were carried out by
adding the unlabelled XRCC1 peptides to 15N-labeled aprataxin
FHA domain. The initial protein concentration was 92 M and
volumes of 2 mM stock solution of peptide were added until the
protein:peptide ratio was 1:4. 1H-SOFAST-HMQC [36] spectra were
measured after each titration step. All spectra were processed
using nmrPipe [37],  and analysed using CARA/NEASY [38]. The
weighted chemical shift change (in ppm units) of each amide
proton (ıHN) and nitrogen (ıN)  was calculated according to
the equation: ıtotal = [(ıHNWHN)
2 +  (ıNWN)2]1/2 with WHN = 1
and WN = 0.154 [39]. Weighted chemical shifts for residues D37,
V45, Q46, V61 and V63 were plotted against peptide concen-
tration to determine individual Kds  and averaged to  determine
the apparent Kd.
3. Results
3.1. APLF and aprataxin FHA interactions with multi-phospho
forms of XRCC1 and XRCC4
APLF and aprataxin bind XRCC1 and XRCC4 following phospho-
rylation by CK2 on several clustered sites in both proteins. These
include the serine and threonine residues within a  core heptapep-
tide sequence, YxxSTDE, found in  both XRCC1 and XRCC4, as well
as subsidiary sites which lie C-terminal to the core motif and differ
between XRCC1 and XRCC4. We used recombinant FHA domains
from aprataxin and APLF in  isothermal titration calorimetry (ITC)
experiments with synthetic phosphopeptides to  determine the
effects on binding of multiple phosphorylation of XRCC1 and XRCC4
within the core motif (Fig. 2A and B; Tables S1 and S2). APLF and
aprataxin can bind both  XRCC1 and XRCC4 peptides phosphory-
lated solely on the threonine in the core motif (XRCC1 Thr519
and XRCC4 Thr233). For  both FHA domains, binding to XRCC4 is
approximately 8-fold tighter than that to  XRCC1. Serine is  con-
served in the pT −1 position (i.e.,  one residue N-terminal to the
pThr) in  both XRCC1 and XRCC4 in all species (Fig. 1B) an additional
phosphorylation of this serine improves binding in  all cases by
factors of between 4- and 11-fold.
A  third putative CK2 site  is located C-terminal to the core motif
in the pT +4 position in both scaffolding proteins; Thr523 in  XRCC1
and Ser237 in XRCC4. Additional phosphorylation at XRCC1 Thr523
marginally but reproducibly improves aprataxin binding by ∼3-fold
with a  smaller effect observed for the addition of pSer237 in XRCC4.
In contrast, no significant improvement in  affinity is observed for
APLF binding to either tri-phosphorylated peptide.
Human XRCC1 contains a fourth predicted CK2-site, Ser525 in
the pT +6 position, but phosphorylation of this residue does not
appreciably increase binding to either APLF or aprataxin. Of  the
CK2 sites identified in XRCC1 and XRCC4 outside the core motif,
only XRCC1 Thr523 (pT +4) is  completely conserved across species
(Fig. 1B). In the light of this and our observation that XRCC1 Ser525
and XRCC4 Ser237 make no significant contributions to  APLF or
aprataxin FHA domain binding, the physiological significance of
these two peripheral sites remains unclear.
Since FHA domains specifically recognise phosphothreonine
residues, we also tested binding to an XRCC1 peptide phospho-
rylated solely on the subsidiary Thr523 (Fig. 2C). Interestingly,
whereas aprataxin has a  clear preference for binding to peptides
phosphorylated on the core threonine in  XRCC1 rather than the
subsidiary one, APLF has approximately equal affinity for both pep-
tides.
3.2. Structure of the APLF-XRCC4 complex
In  order to  determine the structural basis for improved bind-
ing of multiply-phosphorylated peptides to aprataxin and APLF,
weattempted to  co-crystallise these FHA domains with XRCC1
and XRCC4-derived peptides. We were successful in  growing
well diffracting crystals of the APLF FHA domain with a  tri-
phosphorylated XRCC4 peptide. Neither the available structures
of PNKP FHA domain (PDB: 1UJX, 2BRF) nor that of  aprataxin
(PDB:3KT9) proved useful for phasing of these X-ray data by molec-
ular replacement but we were able to solve the structure using
the SAD method and crystals of selenomethionine-substituted pro-
tein and refine against data extending to 1.4 Å resolution (Table 1).
The final model contains two  complexes each comprising residues
1–104 of APLF with an additional five N-terminal-residues derived
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Fig. 2. Multiple phosphorylation of XRCC1 and XRCC4 has additive effects on  FHA domain binding.
Isothermal titration calorimetry of aprataxin (APTX) and APLF  binding to  peptides phosphorylated on  core CK2 XRCC1 sites (A), core CK2 XRCC4 sites (B) and subsidiary CK2
XRCC1  sites (C). Results are representative of experiments performed in triplicate.
from the cleaved GST-tag and the bound tri-phosphorylated XRCC4
phosphopeptide.
Comparison of the APLF FHA domain structure with those of
PNKP [32] and aprataxin [40] shows that, as expected from the
relatively high degree of sequence homology, their FHA domain
-sandwich folds are similar overall (Fig. 3A), although, consistent
with sequence comparison, the APLF structure is  most divergent
and contains a  six-residue extension in loop 6–7.
The overall structure of the peptide complex along with electron
density for the bound XRCC4 peptide is  shown in  Fig.  3B.  The XRCC4
phosphopeptide adopts an orientation similar to that observed
in previously reported FHA/phosphopeptide structures [41],  lying
across the tips of loops 3–4 and 5–6. The core phosphothre-
onine is  secured by a hydrogen-bonding network involving Arg27,
Ser39 and Arg40 (Fig. 3C). A  second set of hydrogen bonds con-
strains the peptide backbone on either side; the Arg27 side-chain
interacts with the pT −2 and the Asn60 side-chain hydrogen-bonds
with the pT +1 carbonyl. Tyr229 in position pT −4 is  held in place
by a  hydrophobic stacking interaction with Pro29. Identical interac-
tions are present in  structures of PNKP bound to an XRCC4 peptide
[42].  In accordance with the lack of binding effect associated with
phosphorylation of Ser237, only residues pT −4  to pT +2  could be
modelled into the electron density, indicating that the C-terminal
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Fig. 3. Structure of APLF-FHA:XRCC4 phosphopeptide complex.
(A)  Sequence alignment and superposition of C backbone structures of the APLF FHA domain (red) aprataxin FHA domain (blue) PNKP FHA domain (grey). The positions of
-strands are indicated by arrows above the sequence alignment and the  five residue insertion between 6-7 is boxed. (B) Ribbon representation showing the 10 -strands
as  red arrows with the molecular surface superimposed. Loops 3–4 and 5–6  involved in peptide binding are  blue. Seven residues of an XRCC4-derived peptide are
shown  in stick representation modeled into 2Fo-Fc density. The phosphothreonine binds in the canonical binding pocket whilst phosphoserine protrudes directly away from
the  FHA domain surface. (C) Schematic representation of protein-peptide contacts between APLF FHA and triphosphorylated XRCC4 peptide. Hydrogen bonds and van der
Waals interactions are denoted by red lines and green crescents respectively.
end  of the peptide, including Asp236 at pT +3, and pSer237 at the
pT +4 position, is mobile.
3.3. NMR  analysis of the aprataxin binding site
We  were not able to  obtain crystals of aprataxin FHA in complex
with any XRCC1 or XRCC4 phosphopeptide, but  were able to use
solution NMR  to examine its interactions with various phosphory-
lated XRCC1 peptides. Triple-resonance experiments were used to
assign the backbone chemical shifts of aprataxin and HMQC titra-
tion experiments with several XRCC1-derived peptides allowed
identification of  the residues involved in binding by chemical-
shift perturbation. This information could then be related to our
previously determined X-ray structure of the aprataxin FHA
domain [40].
Spectra for titrations with core site  mono- di- and tri-
phosphorylated XRCC1 peptides are  essentially identical (Fig. 4A)
but allow us to estimate overall apparent affinities of ∼7 M,
∼2 M  and <1.0 M  M for mono-, di- and tri-phosphorylated pep-
tides, respectively (Table S5). Although the affinity constants for the
tighter binding peptides are  not  well defined due to  the high con-
centration of protein required for the NMR experiment, they are,
nonetheless, broadly consistent with the additional contributions
of the second and third phosphosites measured by ITC. The major-
ity of residues exhibiting chemical shift changes were within loops
3–4 and 5–6 (Fig. 4B). Major shifts of the Arg29 and Ser41 NH
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Fig. 4. Aprataxin phosphopeptide interactions.
(A)  Selected chemical shifts from 1H [36] -SOFAST-HMQC spectra (22 ◦C) of 92 M aprataxin FHA domain, free (black) and in complex in a 1:4 ratio with XRCC1 peptides
YAGSpTDENTDSEEHQ (red), YAGpSpTDENTDSEEHQ (green), YAGpSpTDENpTDSEEHQ (dark blue) and YAGSTDENpTDSEEHQ (cyan). Free and the final bound chemical shift
positions are connected by black lines. (B) Predicted interactions between aprataxin and XRCC1 peptides phosphorylated on  the core-site (yellow sphere) and subsidiary site
(green  sphere). The FHA trace is colored on a  blue to red scale to  indicate the degree of chemical shift movements in 1H [36] -SOFAST-HMQC titrations.
resonances, the major pThr-interacting residues, confirmed that
the peptide binding mode is similar to that generally observed in
other FHA domain systems. In agreement with the APLF/XRCC4
crystal structure, the majority of shifts occur in residues that would
be predicted to interact with peptide positions N-terminal to  the
pThr whilst, NH  shifts for aprataxin residues equivalent to those
that bind to the specificity-defining peptide pT +3 position in  non-
aprataxin family FHA domains, are  sparse or absent. Interestingly,
a similar set of residues was involved in chemical shift changes
associated with binding of the peptide solely phosphorylated on
the subsidiary threonine (Kdapp = 7.0 M),  indicating that it binds
with the phosphothreonine in  the canonical FHA domain phospho-
binding pocket rather than at a distinct site.
3.4. Structural basis of increased affinity for pSpT forms of
XRCC1/4
The XRCC4 peptide contains acidic residues in  positions pT −2,
pT −3, pT +1  and pT +2. The PNKP/XRCC4 complex suggests that
Arg44 provides electrostatic recognition of Glu pT −2  and Asp pT
+1  whilst Lys45 may  provide additional electrostatic recognition of
Asp pT +1 and Glu pT +2  [42]. APLF Arg37, equivalent to PNKP Lys45,
does not form any phosphopeptide interactions, instead assuming
a structural role through two salt bridges with Asp35 in the 3–4
loop of the FHA domain. Side-chain density for APLF Lys36, equiva-
lent to  PNKP Arg44 is very poor suggesting that it is highly mobile.
However, it appears to  be in  a  suitable position for electrostatic
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recognition of both Glu pT −2, Asp pT +1 and pSer at pT −1  (see
below).
The binding studies described above underline clearly the
major contribution of the primary pThr site  in interactions with
both XRCC1 and XRCC4. Of the remaining known phosphoryla-
tion sites within these motifs, the absolutely conserved pSer at pT
−1 shows the greatest additional contribution to overall affinity
of both aprataxin and APLF FHA domains for XRCC1 and XRCC4.
Interestingly, in the APLF/XRCC4 structure the pT −1  phosphoser-
ine assumes an  upright, solvent exposed conformation, making
no direct contacts to FHA domain residues (Fig. 3B). By way
of comparison, the structure of PNKP FHA domain bound to a
tri-phosphorylated XRCC1 peptide shows two major conforma-
tions for the pT −1 phosphoserine of which the lower occupancy
conformation resembles that seen in the APLF/XRCC4 complex.
A second, higher occupancy conformer is  involved in  contacts
with symmetry-related molecules and calcium ions in the lat-
tice but, nevertheless, makes substantial interactions with Arg48
from the 3 to 4 loop. In our  APLF complex, XRCC1 pSer518
is not constrained by crystal contacts but the electron density
is also suggestive of additional, low occupancy conformations.
Importantly, PNKP Arg48 is  conserved in  both APLF (Arg40) and
aprataxin (Arg42), and APLF Arg40 and PNKP Arg48 adopt identi-
cal positions in the respective peptide complex structures (Fig. 5A).
Furthermore, from the APLF and PNKP structures of FHA domains
bound to multiply phosphorylated peptides, Lys36 in APLF, and its
structurally equivalent residues Arg44 in PNKP, and Lys38 in
aprataxin appear to be appropriately positioned for interaction
with the pSer at  the -1 position. Moreover, we have previously
shown that mutation of aprataxin Lys38 substantially reduces
binding to di-phosphorylated pSDpTD CK2 sites within the DNA-
damage mediator protein, Mdc1, where the additional serine
phosphorylation occurs at pT −2  [40].  We  therefore examined
the effects of mutating Arg42 and Lys38 on XRCC1 and XRCC4
peptide binding to  aprataxin (Tables S3 and S4 respectively).
ITC measurements showed that the aprataxin R42A mutation
severely compromised binding to all XRCC1 and XRCC4 pep-
tides, with an interpretable ITC signal only observable for di- and
tri-phosphorylated XRCC1. This presumably reflects loss of the
substantial interactions with the core pThr. Although these data
emphasise the importance of this residue in  overall peptide bind-
ing, it is clearly impossible to  discern any contribution of aprataxin
Arg42 to the additional affinity accrued from accessory serine phos-
phorylation implied by the structural data. However, data from
the aprataxin K38A mutant were more illuminating and showed a
three-fold decrease in binding to  both monophosphorylated XRCC1
and XRCC4 peptides (Fig. 5B). This is likely due to electrostatic
interactions with Asp +1 that is  present in both XRCC1 and XRCC4,
although additional contact with Glu -2 that is only found in XRCC4
may  contribute in  this particular complex. More importantly, we
noted that while the phosphorylation of Ser in the pT −1  posi-
tion increases wild-type aprataxin binding by  ∼11-fold and 8-fold
to XRCC1 and XRCC4 respectively, the effect in the context of the
aprataxin K38A mutant is  significantly reduced in  both cases, sug-
gesting that this residue contributes at least part  of the increased
affinity provided by the accessory Serine ‘-1’ phosphorylation.
4. Discussion
PNKP, APLF and aprataxin contain closely related FHA domains,
through which they bind to  XRCC1 and XRCC4 following phos-
phorylation by CK2.  In addition, we  have previously shown that
aprataxin associates through its FHA domain with diphospho-
rylated pSDpTD CK2 motifs in  Mdc1 [40] that are also sites of
interaction for the FHA and BRCT-repeat domains of the Nbs1 sub-
unit of the Mre11/Rad50/Nbs1 complex [43].  Examination of CK2
sites in XRCC1 and XRCC4 reveals a  common core YxxSTDE motif, in
which both serine and threonine are canonical CK2 sites, with one
or two  subsidiary sites C-terminal to this motif. The close prox-
imity of these sites suggests that more than one phosphate may
contribute to  FHA domain binding. Indeed, studies of  the PNKP
FHA domain have shown that mono- di- and tri- phosphorylated
XRCC1 peptides bind with progressively increasing affinity [32].
Here we have investigated the interactions of XRCC1 and XRCC4
with the two other extant members of this atypical FHA domain
protein family, aprataxin and APLF, by a  combination of  structural
and biochemical approaches.
4.1. Multi-phosphorylation of XRCC1/4 differentially affects FHA
domain affinity and specificity
We have shown that APLF and aprataxin can bind XRCC1
and XRCC4 peptides phosphorylated solely on the core threonine
residue. Affinity for XRCC4 is approximately 8-fold higher in both
cases and PNKP shows a  similar, but less prominent preference
[16,32].  This consistently higher affinity for XRCC4 over XRCC1 is,
most likely, due to the presence of additional acidic residues in
the pT −1  and pT −2  positions in XRCC4 that are absent in XRCC1
and which can form electrostatic interactions with the positively
charged binding surface characteristic of all three FHA domain
structures (see below).
As reported for PNKP/XRCC1 interactions [32], additional phos-
phorylation of Ser at the pT −1  position in  the core motif of XRCC1 or
XRCC4 improves binding affinity for both APLF and aprataxin. How-
ever, the increase in APLF binding to XRCC1 is less (∼3-fold) than for
all other combinations (7–11 fold). Furthermore, phosphorylation
of threonine in the pT +4  position of XRCC1 somewhat increases
binding affinity for aprataxin and PNKP but not for APLF. These com-
bined effects mean that, in  their triphosphorylated states, XRCC1
and XRCC4 bind to  aprataxin with comparable affinities whereas
binding of triphosphorylated XRCC1 to APLF is  26-fold weaker
than that of triphosphorylated XRCC4. Indeed, whilst the aprataxin
domain affinities for both XRCC1 and XRCC4 are clearly influ-
enced by pT +4  phosphorylation, APLF binding is not. Although
APLF has been implicated in repair of both single and double-
stranded breaks [10,18], the significantly greater preference of APLF
for XRCC4 (Fig. 1B)  suggests that its major biological role  is in  NHEJ
of double-stranded lesions, consistent with recent data [44].  Fur-
thermore, we note that no combination of phosphorylations results
in favored binding of APLF for XRCC1 over XRCC4. Thus, APLF shows
a minimum preference for XRCC4 (defined as Kd(XRCC1)/Kd(XRCC4))
of ∼2-fold up  to a  maximum of 26-fold for the triphosphorylated
species. In contrast, as with PNKP, aprataxin shows a  range of speci-
ficities depending on phosphorylation, which vary from a  121-fold
discrimination in  favor of XRCC4 to a 5-fold preference for tri-
phospho XRCC1 over mono-phosphorylated (pT233) XRCC4. Thus,
our data suggest a  mechanism for CK2-dependent modulation of
XRCC1/XRCC4 specificity through patterns of multi-site phospho-
rylation that  decrease the discrimination of aprataxin between
these proteins whilst further increasing the preference of APLF for
XRCC4.
4.2. Surface basicity confers binding versatility
Interactions of APLF, aprataxin and PNKP FHA domains with
either XRCC1 or XRCC4 are additionally stabilized by  approxi-
mately the same degree through phosphorylation of Ser-1. The
crystal structure of an APLF/triphosphorylated XRCC4 complex
showed this phosphoserine in the core motif to occupy a pre-
dominantly upright position facing directly away from the FHA
domain surface. This is  in contrast to the PNKP/triphosphorylated
A.L. Cherry et al. / DNA Repair 35 (2015) 116–125 123
Fig. 5. Contribution of basic residues to phosphopeptide binding.
(A)  Comparison of the electrostatic potential surfaces at  the phosphopeptide-binding sites of the APLF, aprataxin (APTX) and PNKP FHA domains. The structure of the
aprataxin/XRCC4 complex was modelled on  the basis of an  overlap of the X-ray structure of the isolated FHA  [40] with that of the APLF complex (this study). (B) Effect of
aprataxin Lys38 mutation on  XRCC1 and XRCC4 phosphopeptide binding. Binding is decreased relative to  the wild-type 2.7-, 8.5 and 8.8- fold respectively for mono-, di- and
tri-phosphorylated XRCC1 peptides and 3.2-, 7.6- and 9.3-fold respectively for XRCC4 peptides.
XRCC1 structure in which the phosphoserine assumes two con-
formations; one upright and one bent over towards Arg44. NMR
titrations of the aprataxin FHA domain with a di-phosphorylated
peptide did not identify any interacting residues additional to those
implicated in recognition of the mono-phosphorylated peptide.
Nonetheless, the greater effect of serine phosphorylation at the -1
position on binding to wild-type compared with the K38A mutant
aprataxin suggests a  role in  phosphoserine recognition. The equiva-
lent residue in APLF, Lys36, is also in a position to  make electrostatic
interactions with pSer-1, although a lack of density in  our  structure
implies that it is rather mobile. Indeed, it may  be that this lack of
structural order of aprataxin Lys38, APLF Lys36 and PNKP Arg44
enables recognition of pSer in  either the -1 (pSpT; XRCC1/4) or  -2
(pSDpTD; Mdc1) positions in different binding partners. This over-
all versatility appears to  be  a  product of the general distribution of
basic side-chains on the FHA domains that are concentrated on the
surfaces that interact with the N-terminal residues of the XRCC1/4
binding motifs (Fig. 5).  Interestingly, only aprataxin and PNKP
have increased affinity for triphosphorylated XRCC1 and XRCC4.
This may  be attributed to the extended basic surface provided by
aprataxin Lys39 and PNKP Lys45 since the equivalent residue in
APLF, Arg37, is  folded away from the surface. This surface differ-
ence may  also provide an explanation for observation of differing
abilities of these FHA domains to bind poly(ADP-ribose) [45].
4.3. Aprataxin, APLF and PNKP assembly on
multi-phosphorylated XRCC1
Previous studies of the PNKP FHA domain showed that improved
binding affinity observed with increased phosphorylation was
associated with the association of two FHA domains with each
of core (pS518/pT519) and subsidiary (pT523/pS525) sites within
a  single XRCC1 peptide [32]. This led to the proposal of  a  coop-
erative mechanism in  which binding of one FHA domain to  the
core motif promotes binding at the subsidiary site. Our prelimi-
nary ITC observations showed that like PNKP, APLF and aprataxin
are also capable of binding an XRCC1 peptide phosphorylated solely
at Thr523 within the subsidiary site. Supporting NMR  titration
data further indicated that this peptide binds with the phospho-
threonine in  the canonical binding pocket as might be predicted.
Nonetheless, an overall conservation of a ‘PNKP-like’ assembly
mode is not evident. Firstly, our data indicate that dimerisation of
the aprataxin FHA domain does not occur at all and inspection of
surface exposed residues on the 10-11 face of the -sandwich
suggest that Mdc1-like dimerization [46] is  not possible (data not
shown) Secondly, although we did observe a reproducible increase
in stoichiometry for APLF with tri- and tetra-phosphorylated XRCC1
peptides suggestive of 2:1 binding, no indication of co-operativity
elicited through FHA–FHA interactions is evident. Indeed, more
recent binding experiments employing steady-state fluorescence
methods have indicated a 1:1 stoichiometry for binding of  PNKP
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FHA to tetra-phosphorylated XRCC1 [47],  more consonant with our
APLF and aprataxin data. The reasons for the apparent differences
between the two PNKP studies remain unknown and will require
further investigation.
5. Conclusions
DNA damage generates a variety of different lesion types which
each require the action of a  particular array of DNA repair proteins.
The scaffolding proteins XRCC1 and XRCC4 recruit DNA-repair
modulators containing the aprataxin-family FHA domain to the
sites of damage through binding to CK2 phosphorylated sites. A
complete understanding of the regulated recruitment of aprataxin,
APLF and PNKP will require further investigation of the interplay
between their respective FHA-mediated interactions and other fac-
tors such as the involvement of additional binding domains and
patterns of post-translational modification. To this end, we  have
now shown how the FHA-mediated response of PNKP, aprataxin
and APLF to differential phosphorylation of DNA-damage scaffolds
such as XRCC1 and XRCC4 plays a  major role in determining binding
selectivity.
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